PSU Profiles
Keywords
Last Name
Institution

Cara-lynne Schengrund

TitleProfessor Emeritus
InstitutionCollege of Medicine
DepartmentBiochemistry and Molecular Biology
Address500 University Drive Hershey PA 17033
Mailbox: H171
Phone7175318048

 Overview 
 overview
PREFERRED TITLE/ROLE:

Professor Emerita of Biochemistry and Molecular Biology

GRADUATE PROGRAM AFFILIATIONS:

Biochemistry and Molecular Biology, Cell and Molecular Biology, MD/PhD Degree Program, Integrative Biosciences, Neurology

EDUCATION:

Ph.D., Seton Hall University, 1966
Postdoctoral Training, Columbia University College of Physicians and Surgeons, 1967-1969

NARRATIVE:

Biological Role(s) of Gangliosides

Research interests in this laboratory focus on the biological roles of gangliosides, sialylated glycosphingolipids found in greatest concentration in the gray matter of the brain and, at the level of the cell, on the outer surface of the plasma membrane. While the exact cellular function(s) of these lipids is not known, they can enhance process formation by neuroblastoma cells maintained in vitro, and in vivo they can enhance recovery from certain lesions in the central nervous system. We are interested in how gangliosides given ip or iv cross the blood-brain barrier and in identifying which portion(s) of the lipid is needed to induce specific cellular responses. A second interest of this lab is to utilize the fact that gangliosides can function as ligands for the adherence of certain viruses, bacteria, and bacterial toxins as the starting point for the development of inhibitors of the adherence of such pathogens. Using cholera toxin as a model, we found that we could synthesize multivalent oligosaccharides that inhibited its adherence to cell surface associated GM1, a known ligand. Currently, this approach is being used in studies of botulinum neurotoxin A which adheres to the ganglioside GT1b.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Schengrund CL, Ali-Rahmani F, Ramer JC. Cholesterol, GM1, and autism. Neurochem Res. 2012 Jun; 37(6):1201-7.
    View in: PubMed
  2. Ali-Rahmani F, Hengst JA, Connor JR, Schengrund CL. Effect of HFE variants on sphingolipid expression by SH-SY5Y human neuroblastoma cells. Neurochem Res. 2011 Sep; 36(9):1687-96.
    View in: PubMed
  3. Rosa Borges A, Wieczorek L, Johnson B, Benesi AJ, Brown BK, Kensinger RD, Krebs FC, Wigdahl B, Blumenthal R, Puri A, McCutchan FE, Birx DL, Polonis VR, Schengrund CL. Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. Virology. 2010 Dec 5; 408(1):80-8.
    View in: PubMed
  4. Schengrund CL. Lipid rafts: keys to neurodegeneration. Brain Res Bull. 2010 Apr 29; 82(1-2):7-17.
    View in: PubMed
  5. Blome MC, Petro KA, Schengrund CL. Surface plasmon resonance analysis of ricin binding to plasma membranes isolated from NIH 3T3 cells. Anal Biochem. 2010 Jan 15; 396(2):212-6.
    View in: PubMed
  6. Petro KA, Schengrund CL. Membrane raft disruption promotes axonogenesis in n2a neuroblastoma cells. Neurochem Res. 2009 Jan; 34(1):29-37.
    View in: PubMed
  7. Blome MC, Schengrund CL. Multivalent binding of ricin to bovine serum albumin-based neoglycoconjugates. Toxicon. 2008 Jun 1; 51(7):1214-24.
    View in: PubMed
  8. Petro KA, Dyer MA, Yowler BC, Schengrund CL. Disruption of lipid rafts enhances activity of botulinum neurotoxin serotype A. Toxicon. 2006 Dec 15; 48(8):1035-45.
    View in: PubMed
  9. Schengrund CL. Glycoconjugates: roles in neural diseases caused by exogenous pathogens. CNS Neurol Disord Drug Targets. 2006 Aug; 5(4):381-9.
    View in: PubMed
  10. Hartmann SU, Wigdahl B, Neely EB, Berlin CM, Schengrund CL, Lin HM, Howett MK. Biochemical analysis of human milk treated with sodium dodecyl sulfate, an alkyl sulfate microbicide that inactivates human immunodeficiency virus type 1. J Hum Lact. 2006 Feb; 22(1):61-74.
    View in: PubMed
  11. Rosa Borges A, Schengrund CL. Dendrimers and antivirals: a review. Curr Drug Targets Infect Disord. 2005 Sep; 5(3):247-54.
    View in: PubMed
  12. Stine R, Pishko MV, Schengrund CL. Comparison of glycosphingolipids and antibodies as receptor molecules for ricin detection. Anal Chem. 2005 May 1; 77(9):2882-8.
    View in: PubMed
  13. Urdaneta S, Wigdahl B, Neely EB, Berlin CM, Schengrund CL, Lin HM, Howett MK. Inactivation of HIV-1 in breast milk by treatment with the alkyl sulfate microbicide sodium dodecyl sulfate (SDS). Retrovirology. 2005; 2:28.
    View in: PubMed
  14. Yowler BC, Schengrund CL. Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. Biochemistry. 2004 Aug 3; 43(30):9725-31.
    View in: PubMed
  15. Stine R, Pishko MV, Schengrund CL. Heat-stabilized glycosphingolipid films for biosensing applications. Langmuir. 2004 Jul 20; 20(15):6501-6.
    View in: PubMed
  16. Kensinger RD, Catalone BJ, Krebs FC, Wigdahl B, Schengrund CL. Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother. 2004 May; 48(5):1614-23.
    View in: PubMed
  17. Kensinger RD, Yowler BC, Benesi AJ, Schengrund CL. Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120. Bioconjug Chem. 2004 Mar-Apr; 15(2):349-58.
    View in: PubMed
  18. Yowler BC, Schengrund CL. Glycosphingolipids-sweets for botulinum neurotoxin. Glycoconj J. 2004; 21(6):287-93.
    View in: PubMed
  19. Schengrund CL. "Multivalent" saccharides: development of new approaches for inhibiting the effects of glycosphingolipid-binding pathogens. Biochem Pharmacol. 2003 Mar 1; 65(5):699-707.
    View in: PubMed
  20. Yowler BC, Kensinger RD, Schengrund CL. Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J Biol Chem. 2002 Sep 6; 277(36):32815-9.
    View in: PubMed
  21. Jurasinski CV, Lieth E, Dang Do AN, Schengrund CL. Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. Toxicon. 2001 Sep; 39(9):1309-15.
    View in: PubMed
  22. Yowler BC, Stoehr SA, Schengrund CL. Oxidation and base-catalyzed elimination of the saccharide portion of GSLs having very different polarities. J Lipid Res. 2001 Apr; 42(4):659-62.
    View in: PubMed
  23. Schengrund CL, Kovác P. UDP-6-deoxy-6-fluoro-alpha-D-galactose binds to two different galactosyltransferases, but neither can effectively catalyze transfer of the modified galactose to the appropriate acceptor. Carbohydr Res. 1999 Jun 30; 319(1-4):24-8.
    View in: PubMed
  24. Schengrund CL, Kovác P. A simple, nonenzymatic method for desialylating polysialylated ganglio-N-tetraose series gangliosides to produce GM1. J Lipid Res. 1999 Jan; 40(1):160-3.
    View in: PubMed
  25. Thompson JP, Schengrund CL. Inhibition of the adherence of cholera toxin and the heat-labile enterotoxin of Escherichia coli to cell-surface GM1 by oligosaccharide-derivatized dendrimers. Biochem Pharmacol. 1998 Sep 1; 56(5):591-7.
    View in: PubMed
  26. Schengrund CL, Mummert CM. Exogenous gangliosides. How do they cross the blood-brain barrier and how do they inhibit cell proliferation. Ann N Y Acad Sci. 1998 Jun 19; 845:278-84.
    View in: PubMed
  27. Thompson JP, Schengrund CL. Oligosaccharide-derivatized dendrimers: defined multivalent inhibitors of the adherence of the cholera toxin B subunit and the heat labile enterotoxin of E. coli to GM1. Glycoconj J. 1997 Nov; 14(7):837-45.
    View in: PubMed
  28. Mummert CM, Schengrund CL. Nonmuscle myosin heavy chain B is recognized by a monoclonal antibody that inhibits GM1-enhanced neuritogenesis. J Neurochem. 1997 Feb; 68(2):596-600.
    View in: PubMed
  29. Schengrund CL, DasGupta BR, Hughes CA, Ringler NJ. Ganglioside-induced adherence of botulinum and tetanus neurotoxins to adducin. J Neurochem. 1996 Jun; 66(6):2556-61.
    View in: PubMed
  30. Schengrund CL, Chi X, Sabol J, Griffith JW. Long-term effects of instilled mineral dusts on pulmonary surfactant isolated from monkeys. Lung. 1995; 173(3):197-208.
    View in: PubMed
  31. Schengrund CL. Evidence that molecules on the surface of one cell can adhere to the oligosaccharide portion of gangliosides on the surface of another cell. Biol Signals. 1995 Jan-Feb; 4(1):1-13.
    View in: PubMed
  32. Saulino MF, Schengrund CL. Differential accumulation of gangliosides by the brains of MPTP-lesioned mice. J Neurosci Res. 1994 Feb 15; 37(3):384-91.
    View in: PubMed
  33. Saulino MF, Schengrund CL. Effects of specific gangliosides on the in vitro proliferation of MPTP-susceptible cells. J Neurochem. 1993 Oct; 61(4):1277-83.
    View in: PubMed
  34. Schengrund CL, DasGupta BR, Ringler NJ. Ganglioside GD3 enhances adherence of botulinum and tetanus neurotoxins to bovine brain synapsin I. Neurosci Lett. 1993 Aug 20; 158(2):159-62.
    View in: PubMed
  35. Schengrund CL, Ringler NJ, Dasgupta BR. Adherence of botulinum and tetanus neurotoxins to synaptosomal proteins. Brain Res Bull. 1992 Dec; 29(6):917-24.
    View in: PubMed
  36. Fueshko SM, Schengrund CL. Identification of a GM1-binding protein on the surface of murine neuroblastoma cells. J Neurochem. 1992 Aug; 59(2):527-35.
    View in: PubMed
  37. Schengrund CL, DasGupta BR, Ringler NJ. Binding of botulinum and tetanus neurotoxins to ganglioside GT1b and derivatives thereof. J Neurochem. 1991 Sep; 57(3):1024-32.
    View in: PubMed
  38. Fueshko SM, Schengrund CL. Murine neuroblastoma cells express ganglioside binding sites on their cell surface. J Neurochem. 1990 May; 54(5):1791-7.
    View in: PubMed
  39. Schengrund CL. The role(s) of gangliosides in neural differentiation and repair: a perspective. Brain Res Bull. 1990 Jan; 24(1):131-41.
    View in: PubMed
  40. Schengrund CL, Ringler NJ. Binding of Vibrio cholera toxin and the heat-labile enterotoxin of Escherichia coli to GM1, derivatives of GM1, and nonlipid oligosaccharide polyvalent ligands. J Biol Chem. 1989 Aug 5; 264(22):13233-7.
    View in: PubMed
  41. Schengrund CL, Prouty C. Oligosaccharide portion of GM1 enhances process formation by S20Y neuroblastoma cells. J Neurochem. 1988 Jul; 51(1):277-82.
    View in: PubMed
  42. Schengrund CL, Shochat SJ. Gangliosides in neuroblastomas. Neurochem Pathol. 1988 Jun; 8(3):189-202.
    View in: PubMed
  43. Shochat SJ, Corbelletta NL, Repman MA, Schengrund CL. A biochemical analysis of thoracic neuroblastomas: a Pediatric Oncology Group study. J Pediatr Surg. 1987 Jul; 22(7):660-4.
    View in: PubMed
  44. Miljkovic M, Schengrund CL. Oxidative degradation of glycosphingolipids revisited: a simple preparation of oligosaccharides from glycosphingolipids. Carbohydr Res. 1986 Nov 1; 155:175-81.
    View in: PubMed
  45. Schengrund CL, Repman MA. Association of endogenous substrate with solubilized bovine brain sialidase. J Neurosci Res. 1986; 15(2):175-84.
    View in: PubMed
  46. Schengrund CL, Repman MA. Cellular effects of a brain extract factor or factors inhibiting neuroblastoma cell growth in vitro. J Neurosci Res. 1986; 15(3):353-8.
    View in: PubMed
  47. Schengrund CL, Repman MA, Shochat SJ. Ganglioside composition of human neuroblastomas. Correlation with prognosis. A Pediatric Oncology Group Study. Cancer. 1985 Dec 1; 56(11):2640-6.
    View in: PubMed
  48. Schengrund CL, Repman MA. Partial characterization of a brain extract factor(s) inhibitory to transformed neural cells. J Neurosci Res. 1985; 14(3):329-37.
    View in: PubMed
  49. Carine K, Schengrund CL. Effects of exogenous GM1 and GD1a on S20Y neuroblastoma cells. J Neurosci Res. 1984; 12(1):59-69.
    View in: PubMed
  50. Schengrund CL, Repman MA, Sheffler BA. Response of mature mice to challenge with neuroblastoma after inoculation with neuroblastoma cells as neonates. Cancer Lett. 1982 Nov-Dec; 17(2):229-35.
    View in: PubMed
  51. Schengrund CL, Repman MA. Density-dependent changes in gangliosides and sialidase activity of murine neuroblastoma cells. J Neurochem. 1982 Oct; 39(4):940-7.
    View in: PubMed
  52. Schengrund CL, Sheffler BA. Biochemical and morphological study of adriamycin-induced changes in murine neuroblastoma cells. Oncology. 1982; 39(3):185-90.
    View in: PubMed
  53. Ransom JH, Schengrund CL, Bartlett GL. Solubilization and partial characterization of a tumor-rejection antigen from an ultraviolet light-induced murine tumor. Int J Cancer. 1981; 27(4):545-54.
    View in: PubMed
  54. Schengrund CL, Marangos PJ. Neuron-specific enolase levels in primary cultures of neurons. J Neurosci Res. 1980; 5(4):305-11.
    View in: PubMed
  55. Schengrund CL, Repman MA. Differential enrichment of cells from embryonic rat cerebra by centrifugal elutriation. J Neurochem. 1979 Jul; 33(1):283-9.
    View in: PubMed
  56. Schengrund CL, Repman MA, Nelson JT. Distribution in spleen subcellular organelles of sialidase active towards natural sialogylcolipid and sialoglycoprotein substrates. Biochim Biophys Acta. 1979 Jun 6; 568(2):377-85.
    View in: PubMed
  57. Sheffler BA, Repman MA, Schengrund CL. Development of a neonatal and metastatic murine neuroblastoma model. Cancer Res. 1979 Mar; 39(3):711-3.
    View in: PubMed
  58. Zagon IS, Schengrund CL. Neuronal and non-neuronal properties of neuroblastoma cells. Exp Cell Res. 1978 Jun; 114(1):159-65.
    View in: PubMed
  59. Changaris DG, Schengrund CL, Combs JW. Microfluorimetry of brain glycolipid. Theoretical and applied analysis of PAS fluorescence and dye concentration. J Histochem Cytochem. 1978 Apr; 26(4):267-76.
    View in: PubMed
  60. Schengrund CL, Repman MA. Cell culture of sixteen-day-old rat embryo cerebra and associated changes in ganglioside pattern. J Neurochem. 1977 Nov; 29(5):923-7.
    View in: PubMed
  61. Shochat SJ, Abt AB, Schengrund CL. VCN-releasable sialic acid and gangliosides in human neuroblastomas. J Pediatr Surg. 1977 Jun; 12(3):413-8.
    View in: PubMed
  62. Schengrund CL, Rosenberg A, Repman MA. Ecto-ganglioside-sialidase activity of herpes simplex virus-transformed hamster embryo fibroblasts. J Cell Biol. 1976 Sep; 70(3):555-61.
    View in: PubMed
  63. Schengrund CL, Nelson JT. Ganglioside sialidase activity in bovine neuronal perikarya. Neurochem Res. 1976 Apr; 1(2):171-80.
    View in: PubMed
  64. Schengrund CL, Nelson JT. Sialidase activity in mouse neuroblastoma cell lines. Neurochem Res. 1976 Apr; 1(2):181-90.
    View in: PubMed
  65. Schengrund CL, Nelson JT. Influence of cation concentration on the sialidase activity of neuronal synaptic membranes. Biochem Biophys Res Commun. 1975 Mar 3; 63(1):217-23.
    View in: PubMed
  66. Schengrund CL, Duff R, Rosenberg A. Sialidase activity of oncogenic cells transformed by herpes simplex virus. Virology. 1974 Apr; 58(2):595-9.
    View in: PubMed
  67. Schengrund CL, Lausch RN, Rosenberg A. Sialidase activity in transformed cells. J Biol Chem. 1973 Jun 25; 248(12):4424-8.
    View in: PubMed
  68. Schengrund CL, Jensen DS, Rosenberg A. Localization of sialidase in the plasma membrane of rat liver cells. J Biol Chem. 1972 May 10; 247(9):2742-6.
    View in: PubMed
  69. Schengrund CL, Rosenberg A. Gangliosides, glycosidases, and sialidase in the brain and eyes of developing chickens. Biochemistry. 1971 Jun 8; 10(12):2424-8.
    View in: PubMed
  70. Schengrund CL, Rosenberg A. Intracellular location and properties of bovine brain sialidase. J Biol Chem. 1970 Nov 25; 245(22):6196-200.
    View in: PubMed
  71. Schengrund CL, Garrigan OW. A comparative study of gangliosides from brains of various species. Lipids. 1969 Nov; 4(6):488-95.
    View in: PubMed
  72. Schengrund C, Krasna AI. Purification and properties of the light-activated hydrogenase of Proteus vulgaris. Biochim Biophys Acta. 1969; 185(2):332-7.
    View in: PubMed
Schengrund's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_